MBRX (Moleculin Biotech) Total Liabilities: $8.18 Mil (As of Mar. 2026)


MBRX Moleculin Biotech Inc MBRX
30 GF Score
Price $3.57
! 1 Warning Sign
View Full Analysis

What is Moleculin Biotech Total Liabilities?

Moleculin Biotech MBRX +9.51% 30 Total Liabilities is $8.18 Mil as of Mar. 2026. GuruFocus rates MBRX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Moleculin Biotech's Total Liabilities for the quarter that ended in Mar. 2026 was $8.18 Mil.

Moleculin Biotech's quarterly Total Liabilities declined from Sep. 2025 ($47.27 Mil) to Dec. 2025 ($7.12 Mil) but then increased from Dec. 2025 ($7.12 Mil) to Mar. 2026 ($8.18 Mil).

Moleculin Biotech's annual Total Liabilities declined from Dec. 2023 ($12.14 Mil) to Dec. 2024 ($5.72 Mil) but then increased from Dec. 2024 ($5.72 Mil) to Dec. 2025 ($7.12 Mil).

Moleculin Biotech Total Liabilities Historical Data

* Premium members only.

The historical data trend for Moleculin Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moleculin Biotech Total Liabilities Chart

Moleculin Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.10 5.23 12.14 5.72 7.12

Moleculin Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.97 28.76 47.27 7.12 8.18
MBRX
30GF Score
Moleculin Biotech Inc MBRX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moleculin Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Moleculin Biotech's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.854+(0.222+0.044
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=7.12

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=22.126-15.006
=7.12

Moleculin Biotech's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.962+(0.185+0.033
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=8.18

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=23.363-15.183
=8.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $8.18 Mil mean?
Moleculin Biotech (MBRX) has a Total Liabilities of $8.18 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Moleculin Biotech and its competitors.
Is Moleculin Biotech's Total Liabilities too high?
Moleculin Biotech's current Total Liabilities is $8.18 Mil. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Moleculin Biotech's Total Liabilities compare to JAGX and BCDA?
Moleculin Biotech's Total Liabilities of $8.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Moleculin Biotech and its competitors. Moleculin Biotech's current Total Liabilities is $8.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moleculin Biotech stock overvalued right now?
Moleculin Biotech (MBRX) has a current Total Liabilities of $8.18 Mil. The current Total Liabilities is $8.18 Mil. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current Total Liabilities is $8.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Moleculin Biotech Business Description

Other Exchanges 0K2H:UK
Address 5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
30GF Score

Get the complete analysis for MBRX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.57
Price